{"id":"phenylpropanolamine","rwe":[],"tags":[{"label":"Indirectly Acting Sympathomimetic Amines","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sodium-dependent noradrenaline transporter","category":"target"},{"label":"SLC6A2","category":"gene"},{"label":"SLC6A3","category":"gene"},{"label":"ADRA2C","category":"gene"},{"label":"R01BA01","category":"atc"},{"label":"Active","category":"status"},{"label":"Allergic conjunctivitis","category":"indication"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Common cold","category":"indication"},{"label":"Cough","category":"indication"},{"label":"Influenza-like symptoms","category":"indication"},{"label":"Nasal congestion","category":"indication"},{"label":"Alpharma Us Pharms","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Agonists","category":"pharmacology"},{"label":"Adrenergic alpha-Agonists","category":"pharmacology"},{"label":"Anti-Obesity Agents","category":"pharmacology"},{"label":"Appetite Depressants","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Nasal Decongestants","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Respiratory System Agents","category":"pharmacology"},{"label":"Sympathomimetics","category":"pharmacology"},{"label":"Vasoconstrictor Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":40.679,"date":"","count":9,"signal":"Sudden cardiac death","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=41)"}],"drugInteractions":[{"url":"/drug/rasagiline","drug":"rasagiline","action":"Avoid combination","effect":"May interact with Rasagiline","source":"DrugCentral","drugSlug":"rasagiline"},{"url":"/drug/tranylcypromine","drug":"tranylcypromine","action":"Avoid combination","effect":"May interact with Tranylcypromine","source":"DrugCentral","drugSlug":"tranylcypromine"}],"commonSideEffects":[],"contraindications":["Acidosis","Acute abdominal pain","Acute erosive gastritis","Acute hepatitis","Acute nephropathy","Acute pancreatitis","Agoraphobia","Alcohol intoxication","Alcohol withdrawal delirium","Alcoholism","Anemia","Anemia due to enzyme deficiency","Angle-closure glaucoma","Arterial thrombosis","Arteriosclerotic vascular disease","Asthenia","Benign intracranial hypertension","Benign prostatic hyperplasia","Bladder outflow obstruction","Bradycardia","Breastfeeding (mother)","Central nervous system depression","Chronic heart failure","Chronic idiopathic constipation","Chronic obstructive lung disease"]},"trials":[],"aliases":[],"company":"Alpharma Us Pharms","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PHENYLPROPANOLAMINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:19:22.774313+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:19:27.965322+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PHENYLPROPANOLAMINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:19:28.345465+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Norepinephrine transporter releasing agent","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:19:29.413339+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200695/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:19:29.063651+00:00"}},"allNames":"propadrine","offLabel":[],"synonyms":["phenylpropanolamine","norephedrine","propadrine","(+/-)-phenylpropanolamine","phenylpropanolamine hydrochloride","phenylpropanolamine HCl","phenylpropanolamine polistirex"],"timeline":[{"date":"2000-09-29","type":"positive","source":"DrugCentral","milestone":"FDA approval (Alpharma Us Pharms)"}],"approvals":[{"date":"2000-09-29","orphan":false,"company":"ALPHARMA US PHARMS","regulator":"FDA"}],"brandName":"Propadrine","ecosystem":[{"indication":"Allergic conjunctivitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alcaftadine","slug":"alcaftadine","company":"Allergan"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Common cold","otherDrugs":[{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"azatadine","slug":"azatadine","company":""}],"globalPrevalence":null},{"indication":"Cough","otherDrugs":[{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"benzocaine","slug":"benzocaine","company":""},{"name":"benzonatate","slug":"benzonatate","company":"Pfizer"},{"name":"bromazine","slug":"bromazine","company":"Forest Labs"}],"globalPrevalence":null},{"indication":"Influenza-like symptoms","otherDrugs":[{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"brompheniramine","slug":"brompheniramine","company":""},{"name":"caffeine","slug":"caffeine","company":"Novartis"},{"name":"chlorphenamine","slug":"chlorphenamine","company":"Bayer Healthcare Llc"}],"globalPrevalence":null},{"indication":"Nasal congestion","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Nasal discharge","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"ammonium chloride","slug":"ammonium-chloride","company":"B Braun"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":30000000},{"indication":"Rhinitis","otherDrugs":[{"name":"beclometasone dipropionate","slug":"beclometasone-dipropionate","company":""},{"name":"clofedanol","slug":"clofedanol","company":""},{"name":"codeine","slug":"codeine","company":"Ani Pharms"},{"name":"dextromethorphan","slug":"dextromethorphan","company":"Ani Pharms"}],"globalPrevalence":null}],"mechanism":{"target":"Sodium-dependent noradrenaline transporter","novelty":"Follow-on","targets":[{"gene":"SLC6A2","source":"DrugCentral","target":"Sodium-dependent noradrenaline transporter","protein":"Sodium-dependent noradrenaline transporter"},{"gene":"SLC6A3","source":"DrugCentral","target":"Sodium-dependent dopamine transporter","protein":"Sodium-dependent dopamine transporter"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"},{"gene":"ADRA2A","source":"DrugCentral","target":"Alpha-2A adrenergic receptor","protein":"Alpha-2A adrenergic receptor"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor"},{"gene":"CHRM1","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M1","protein":"Muscarinic acetylcholine receptor M1"},{"gene":"HTR7","source":"DrugCentral","target":"5-hydroxytryptamine receptor 7","protein":"5-hydroxytryptamine receptor 7"},{"gene":"ADRA1A","source":"DrugCentral","target":"Alpha-1A adrenergic receptor","protein":"Alpha-1A adrenergic receptor"},{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"}],"modality":"Small Molecule","drugClass":"Indirectly Acting Sympathomimetic Amines","explanation":"","oneSentence":"","technicalDetail":"Propadrine acts as an indirectly acting sympathomimetic amine by inhibiting the sodium-dependent noradrenaline transporter (NET), which increases the levels of noradrenaline in the synaptic cleft and stimulates the sympathetic nervous system."},"commercial":{"launchDate":"2000","_launchSource":"DrugCentral (FDA 2000-09-29, ALPHARMA US PHARMS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2149","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=PHENYLPROPANOLAMINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PHENYLPROPANOLAMINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:19:31.357802","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:19:30.755938+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"pseudoephedrine","drugSlug":"pseudoephedrine","fdaApproval":"1963-10-18","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"phenylephrine","drugSlug":"phenylephrine","fdaApproval":"1952-01-21","patentExpiry":"Sep 26, 2036","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"phenylpropanolamine","indications":{"approved":[{"name":"Allergic conjunctivitis","source":"DrugCentral","snomedId":473460002,"regulator":"FDA"},{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA"},{"name":"Common cold","source":"DrugCentral","snomedId":82272006,"regulator":"FDA"},{"name":"Cough","source":"DrugCentral","snomedId":49727002,"regulator":"FDA"},{"name":"Influenza-like symptoms","source":"DrugCentral","snomedId":315642008,"regulator":"FDA"},{"name":"Nasal congestion","source":"DrugCentral","snomedId":68235000,"regulator":"FDA"},{"name":"Nasal discharge","source":"DrugCentral","snomedId":64531003,"regulator":"FDA","usPrevalence":null,"globalPrevalence":30000000,"prevalenceMethod":"curated","prevalenceSource":"Influenza Other Respir Viruses, 2023 (PMID:36824394)"},{"name":"Rhinitis","source":"DrugCentral","snomedId":70076002,"regulator":"FDA"},{"name":"Seasonal allergic rhinitis","source":"DrugCentral","snomedId":367498001,"regulator":"FDA"},{"name":"Sinus headache","source":"DrugCentral","snomedId":4969004,"regulator":"FDA"},{"name":"Sneezing","source":"DrugCentral","snomedId":76067001,"regulator":"FDA"},{"name":"Vasomotor rhinitis","source":"DrugCentral","snomedId":8229003,"regulator":"FDA"}],"offLabel":[{"name":"Obesity","source":"DrugCentral","drugName":"PHENYLPROPANOLAMINE","evidenceCount":81,"evidenceLevel":"strong"},{"name":"Urinary incontinence","source":"DrugCentral","drugName":"PHENYLPROPANOLAMINE"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"pseudoephedrine","brandName":"pseudoephedrine","genericName":"pseudoephedrine","approvalYear":"1963","relationship":"same-class"},{"drugId":"phenylephrine","brandName":"phenylephrine","genericName":"phenylephrine","approvalYear":"1952","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06044935","phase":"NA","title":"Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2024-01-08","conditions":["Overweight","Obesity"],"enrollment":100,"completionDate":"2028-01-31"},{"nctId":"NCT02763033","phase":"PHASE2","title":"Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2017-04-26","conditions":["Hematopoietic Stem Cell Transplantation"],"enrollment":107,"completionDate":"2025-12-29"},{"nctId":"NCT05469997","phase":"NA","title":"Ketogenic Diet Interventions in Parkinson's Disease: Safeguarding the Gut Microbiome","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2023-03-01","conditions":["Parkinson Disease"],"enrollment":52,"completionDate":"2024-10-30"},{"nctId":"NCT05843669","phase":"PHASE4","title":"A Study to Explore if Long-term Use of Mucinex Can Help With Symptoms in Patients With Stable Chronic Bronchitis.","status":"COMPLETED","sponsor":"American Health Research","startDate":"2023-07-17","conditions":["Chronic Bronchitis"],"enrollment":82,"completionDate":"2024-11-13"},{"nctId":"NCT05362292","phase":"PHASE4","title":"TReating Incontinence for Underlying Mental and Physical Health","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-10-04","conditions":["Urinary Incontinence, Urge","Urinary Incontinence","Overactive Bladder","Incontinence, Urge","Incontinence, Urinary","Incontinence"],"enrollment":270,"completionDate":"2027-08-02"},{"nctId":"NCT06412588","phase":"NA","title":"Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-06-15","conditions":["Helicobacter Pylori Infection"],"enrollment":579,"completionDate":"2026-01-10"},{"nctId":"NCT05911399","phase":"","title":"Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency","status":"AVAILABLE","sponsor":"Rare Thyroid Therapeutics International AB","startDate":"","conditions":["Monocarboxylate Transporter 8 Deficiency","Allan-Herndon-Dudley Syndrome"],"enrollment":0,"completionDate":""},{"nctId":"NCT02396459","phase":"PHASE2","title":"Triac Trial II in MCT8 Deficiency Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rare Thyroid Therapeutics International AB","startDate":"2020-12-07","conditions":["Allan-Herndon-Dudley Syndrome"],"enrollment":22,"completionDate":"2027-08-18"},{"nctId":"NCT07335588","phase":"PHASE3","title":"A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus","status":"NOT_YET_RECRUITING","sponsor":"LEO Pharma","startDate":"2026-05-06","conditions":["Lichen Sclerosus"],"enrollment":652,"completionDate":"2028-12-29"},{"nctId":"NCT06716645","phase":"PHASE4","title":"A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin","status":"COMPLETED","sponsor":"HALEON","startDate":"2024-12-04","conditions":["Common Cold","Cough"],"enrollment":244,"completionDate":"2025-02-14"},{"nctId":"NCT07398924","phase":"NA","title":"Vaginal Estradiol and Oral Guaifenesin in Clomiphene Ovulation Induction","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2022-01-06","conditions":["Female Infertility","Anovulatory Infertility","Unexplained Infertility"],"enrollment":90,"completionDate":"2023-06-23"},{"nctId":"NCT05579327","phase":"PHASE3","title":"Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)","status":"COMPLETED","sponsor":"Rare Thyroid Therapeutics International AB","startDate":"2023-07-21","conditions":["Monocarboxylate Transporter 8 Deficiency","Allan-Herndon-Dudley Syndrome"],"enrollment":20,"completionDate":"2025-09-03"},{"nctId":"NCT06310967","phase":"PHASE1,PHASE2","title":"A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease","status":"RECRUITING","sponsor":"Intelligem Therapeutics Australia Pty Ltd.","startDate":"2024-11-12","conditions":["Hyperuricemia","Hypouricemia, Renal"],"enrollment":60,"completionDate":"2027-01"},{"nctId":"NCT03952299","phase":"PHASE3","title":"Oxybutynin for Post-surgical Bladder Pain and Urgency","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2021-09-01","conditions":["Overactive Bladder Syndrome","Neuropathic Bladder"],"enrollment":100,"completionDate":"2026-12-31"},{"nctId":"NCT07314775","phase":"PHASE4","title":"Yangxin Dawayimixike Honey Paste for Carotid Atherosclerotic Plaque With Dyslipidemia: A Randomized Controlled Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Xinjiang Uygur Pharmaceutical Co., Ltd.","startDate":"2026-01","conditions":["Dyslipidemia","Carotid Atherosclerotic Plaques"],"enrollment":422,"completionDate":"2029-01"},{"nctId":"NCT07312721","phase":"PHASE4","title":"Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis","status":"COMPLETED","sponsor":"Azfar Farogh","startDate":"2024-01-05","conditions":["Helicobacter Pylori Infection","Chronic Gastritis","Peptic Ulcer Disease"],"enrollment":752,"completionDate":"2024-12-30"},{"nctId":"NCT05603832","phase":"PHASE3","title":"A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement","status":"COMPLETED","sponsor":"Arthritis Innovation Corporation","startDate":"2022-11-17","conditions":["Post Operative Pain"],"enrollment":151,"completionDate":"2024-08-23"},{"nctId":"NCT07288528","phase":"PHASE4","title":"A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2026-04-01","conditions":["Cough","Refractory Chronic Cough","Unexplained Chronic Cough","Cough Hypersensitivity Syndrome","Chronic Cough"],"enrollment":124,"completionDate":"2029-07-01"},{"nctId":"NCT07242443","phase":"PHASE4","title":"Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori）","status":"NOT_YET_RECRUITING","sponsor":"First People's Hospital of Hangzhou","startDate":"2025-11-20","conditions":["HELICOBACTER PYLORI INFECTIONS"],"enrollment":240,"completionDate":"2026-12-31"},{"nctId":"NCT06659965","phase":"","title":"Intravenous Methocarbamol for Acute Pain After Spine Surgery","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2020-01-01","conditions":["Acute Post Operative Pain","Postsurgical Pain Management","Spine Surgery","Acute Pain, Postoperative","Multimodal Analgesia"],"enrollment":1270,"completionDate":"2025-06-30"},{"nctId":"NCT05775848","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ML Bio Solutions, Inc.","startDate":"2023-05-31","conditions":["Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)"],"enrollment":81,"completionDate":"2027-07"},{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":["Helicobacter Pylori Infection"],"enrollment":450,"completionDate":"2025-12"},{"nctId":"NCT05857163","phase":"PHASE3","title":"Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2023-05-18","conditions":["H.Pylori Infection"],"enrollment":700,"completionDate":"2024-03-26"},{"nctId":"NCT07114640","phase":"PHASE3","title":"The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Far Eastern Memorial Hospital","startDate":"2025-08-07","conditions":["Urinary Bladder, Overactive"],"enrollment":220,"completionDate":"2028-12-31"},{"nctId":"NCT04923659","phase":"EARLY_PHASE1","title":"Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-05-25","conditions":["Low Intensity Focussed Ultrasound"],"enrollment":20,"completionDate":"2026-05"},{"nctId":"NCT02982876","phase":"NA","title":"Airway Stents for Excessive Dynamic Airway Collapse","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2016-12","conditions":["Tracheobronchomalacia","Excessive Dynamic Airway Collapse"],"enrollment":50,"completionDate":"2024-12-31"},{"nctId":"NCT05100017","phase":"NA","title":"Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2021-09-30","conditions":["Kidney Calculi","Kidney Diseases","Nephrolithiasis","Urolithiasis","Ureteral Diseases","Ureteral Calculi"],"enrollment":126,"completionDate":"2025-12"},{"nctId":"NCT05388929","phase":"PHASE4","title":"Methocarbamol in Ventral and Inguinal HR","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prisma Health-Upstate","startDate":"2022-06-23","conditions":["Ventral Hernia","Inguinal Hernia"],"enrollment":164,"completionDate":"2026-12"},{"nctId":"NCT07046156","phase":"","title":"Treatment of Overactive Bladder With Anticholinergic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital","startDate":"2022-09-01","conditions":["Overactive Bladder"],"enrollment":120,"completionDate":"2026-06-01"},{"nctId":"NCT05076110","phase":"PHASE4","title":"Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-04-07","conditions":["Hip Arthroscopy"],"enrollment":188,"completionDate":"2026-04"},{"nctId":"NCT06964334","phase":"PHASE3","title":"The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-06-01","conditions":["Helicobacter Pylori Infection"],"enrollment":70,"completionDate":"2026-08-01"},{"nctId":"NCT06959784","phase":"PHASE4","title":"Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)","status":"ENROLLING_BY_INVITATION","sponsor":"China-Japan Friendship Hospital","startDate":"2024-01-01","conditions":["Diabetes Mellitus","Cardiovascular Diseases","Cerebrovascular Disease"],"enrollment":142,"completionDate":"2026-12-31"},{"nctId":"NCT06918756","phase":"","title":"Development of a Cough Control Questionnaire (CCQ)","status":"RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2025-04-01","conditions":["Cough"],"enrollment":100,"completionDate":"2031-09-01"},{"nctId":"NCT04767074","phase":"NA","title":"A Non-pharmacological Cough Control Therapy","status":"RECRUITING","sponsor":"West Park Healthcare Centre","startDate":"2020-09-01","conditions":["Cough","ILD","Pulmonary Disease","Pulmonary Fibrosis"],"enrollment":24,"completionDate":"2025-12"},{"nctId":"NCT06862687","phase":"NA","title":"Arteriovenous Fistula Pain and Cold Application","status":"COMPLETED","sponsor":"Ataturk University","startDate":"2024-05-01","conditions":["Arteriovenous Fistula Pain"],"enrollment":48,"completionDate":"2024-12-01"},{"nctId":"NCT03076021","phase":"PHASE4","title":"Effects of Isotretinoin on CYP2D6 Activity","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-07-26","conditions":["CYP2D6 Polymorphism"],"enrollment":33,"completionDate":"2023-11-27"},{"nctId":"NCT06782893","phase":"NA","title":"Chronic COUGH Management in Interstitial Lung DisEase","status":"NOT_YET_RECRUITING","sponsor":"Aveiro University","startDate":"2027-12-20","conditions":["Interstitial Lung Disease","Chronic Cough"],"enrollment":60,"completionDate":"2028-07-30"},{"nctId":"NCT06482086","phase":"PHASE2","title":"Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2021-06-01","conditions":["Locally Advanced Thyroid Gland Carcinoma"],"enrollment":75,"completionDate":"2025-12-01"},{"nctId":"NCT00688688","phase":"PHASE3","title":"Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-04-25","conditions":["Urinary Bladder, Overactive"],"enrollment":2792,"completionDate":"2010-05-06"},{"nctId":"NCT00689104","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-04-28","conditions":["Urinary Bladder, Overactive"],"enrollment":2336,"completionDate":"2009-03-24"},{"nctId":"NCT00966004","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-07-24","conditions":["Urinary Bladder, Overactive"],"enrollment":1139,"completionDate":"2010-02-15"},{"nctId":"NCT02294396","phase":"PHASE4","title":"Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-10-28","conditions":["Overactive Bladder (OAB)"],"enrollment":649,"completionDate":"2016-09-07"},{"nctId":"NCT01043666","phase":"PHASE3","title":"A Study of YM178 in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-12-21","conditions":["Urinary Bladder, Overactive"],"enrollment":1126,"completionDate":"2011-09-16"},{"nctId":"NCT01604928","phase":"PHASE2","title":"Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2004-04-05","conditions":["Urinary Bladder, Overactive"],"enrollment":260,"completionDate":"2005-01-25"},{"nctId":"NCT03602508","phase":"","title":"Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2018-07-20","conditions":["Overactive Bladder (OAB)"],"enrollment":5589,"completionDate":"2019-09-13"},{"nctId":"NCT02386072","phase":"","title":"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Scientific & Medical Affairs, Inc.","startDate":"2015-01-05","conditions":["Urinary Bladder Overactive","Overactive Bladder","Urinary Bladder Diseases","Urologic Diseases"],"enrollment":1524,"completionDate":"2017-08-04"},{"nctId":"NCT06640439","phase":"EARLY_PHASE1","title":"LED Therapy for Third Molar Surgery","status":"NOT_YET_RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-10-14","conditions":["Molar, Third","Photobiomodulation","Photobiomodulation Therapy","Third Molar Surgery"],"enrollment":50,"completionDate":"2025-04-14"},{"nctId":"NCT06591494","phase":"PHASE2,PHASE3","title":"The Efficacy of Quadruple Therapy Containing Sodium Bicarbonate as the Primary Treatment for Helicobacter Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-09-15","conditions":["Helicobacter Pylori Infection"],"enrollment":855,"completionDate":"2025-12-30"},{"nctId":"NCT00523068","phase":"PHASE4","title":"Pharmacological vs Surgical Treatment for Mixed Incontinence","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2007-09","conditions":["Mixed Urinary Incontinence","Urinary Incontinence, Stress","Urinary Incontinence, Urge"],"enrollment":0,"completionDate":"2010-01"},{"nctId":"NCT03194945","phase":"PHASE4","title":"Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2017-11-01","conditions":["Type 2 Diabetes Mellitus"],"enrollment":412,"completionDate":"2022-12-31"},{"nctId":"NCT04887194","phase":"PHASE1","title":"PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates","status":"COMPLETED","sponsor":"Mirati Therapeutics Inc.","startDate":"2021-04-08","conditions":["Advanced Solid Tumor"],"enrollment":40,"completionDate":"2022-12-22"},{"nctId":"NCT00649129","phase":"PHASE1","title":"Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-07","conditions":["Healthy"],"enrollment":36,"completionDate":"2002-08"},{"nctId":"NCT00650481","phase":"PHASE1","title":"Fasting Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-12","conditions":["Healthy"],"enrollment":60,"completionDate":"2003-01"},{"nctId":"NCT00649259","phase":"PHASE1","title":"Food Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-10","conditions":["Healthy"],"enrollment":39,"completionDate":"2002-11"},{"nctId":"NCT00648843","phase":"PHASE1","title":"Food Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-12","conditions":["Healthy"],"enrollment":28,"completionDate":"2003-01"},{"nctId":"NCT00649727","phase":"PHASE1","title":"Fed Study of Oxybutynin Chloride Extended-release Tablets 10 mg and Ditropan XL® Tablets 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-07","conditions":["Healthy"],"enrollment":24,"completionDate":"2002-08"},{"nctId":"NCT05378360","phase":"PHASE2","title":"DWP708 for Treating Epidermal Growth Factor Receptor Inhibitor Related Skin Toxicities","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-05-02","conditions":["Rash Acneiform"],"enrollment":96,"completionDate":"2023-12-28"},{"nctId":"NCT01829295","phase":"PHASE3","title":"Methotrexate and Mycophenolate Mofetil for UVEITIS","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2013-08","conditions":["Uveitis"],"enrollment":216,"completionDate":"2018-08-09"},{"nctId":"NCT05084599","phase":"PHASE4","title":"Effect of 90% Effective Dose of Metaraminol in Supine and Left Tilt Positions on Cesarean Section","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2022-05-12","conditions":["Cesarean Section Complications"],"enrollment":124,"completionDate":"2024-01-31"},{"nctId":"NCT06076694","phase":"PHASE2","title":"Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2022-06-26","conditions":["Helicobacter Pylori Infection"],"enrollment":80,"completionDate":"2022-09-20"},{"nctId":"NCT03779074","phase":"PHASE3","title":"Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2018-09-03","conditions":["Helicobacter Pylori Infection"],"enrollment":918,"completionDate":"2021-12-31"},{"nctId":"NCT05628636","phase":"PHASE1","title":"AC-OLE-01-VA Tolerability Study in Healthy Participants Under Different Dosing Conditions","status":"COMPLETED","sponsor":"Cerecin","startDate":"2022-11-14","conditions":["Alzheimer Disease"],"enrollment":18,"completionDate":"2023-04-03"},{"nctId":"NCT05946902","phase":"PHASE4","title":"Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study","status":"UNKNOWN","sponsor":"Far Eastern Memorial Hospital","startDate":"2023-09-12","conditions":["Female Patients With Overactive Bladder Syndrome"],"enrollment":150,"completionDate":"2024-07-31"},{"nctId":"NCT03468478","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2017-06-18","conditions":["Kidney Transplant Infection"],"enrollment":1209,"completionDate":"2021-08-23"},{"nctId":"NCT02373280","phase":"NA","title":"The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-08","conditions":["Helicobacter Infection"],"enrollment":600,"completionDate":"2024-12"},{"nctId":"NCT05764668","phase":"PHASE3","title":"Efficacy and Safety of Zihua Wenfei Granules in Treatment of Postinfectious Cough (Wind-cold Invading Lungs Syndrome)","status":"UNKNOWN","sponsor":"DoCare Pharmaceutial Technology Co.,Ltd","startDate":"2022-11-15","conditions":["Cough"],"enrollment":480,"completionDate":"2024-08"},{"nctId":"NCT03867123","phase":"PHASE1","title":"A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients","status":"COMPLETED","sponsor":"Laminar Pharmaceuticals","startDate":"2018-12-04","conditions":["Glioblastoma (GBM)"],"enrollment":18,"completionDate":"2020-07-01"},{"nctId":"NCT05658692","phase":"PHASE4","title":"Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-10-01","conditions":["Acute Respiratory Distress Syndrome"],"enrollment":1000,"completionDate":"2023-12"},{"nctId":"NCT04090190","phase":"PHASE4","title":"Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-10-30","conditions":["Urinary Incontinence","Urgency Urinary"],"enrollment":20,"completionDate":"2021-10-31"},{"nctId":"NCT02908750","phase":"PHASE1","title":"Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-02","conditions":["Non Small Cell Lung Cancer"],"enrollment":24,"completionDate":"2022-10-11"},{"nctId":"NCT02374021","phase":"PHASE4","title":"Treatments Against RA and Effect on FDG-PET/CT","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-07","conditions":["Arthritis, Rheumatoid"],"enrollment":159,"completionDate":"2021-05"},{"nctId":"NCT05551091","phase":"NA","title":"Glycomacropeptide and Women's Health","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-04-09","conditions":["Obesity"],"enrollment":13,"completionDate":"2022-07-05"},{"nctId":"NCT03738917","phase":"PHASE4","title":"Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Acute Bronchitis.","status":"COMPLETED","sponsor":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","startDate":"2019-02-01","conditions":["Acute Bronchitis"],"enrollment":668,"completionDate":"2021-12-31"},{"nctId":"NCT04500860","phase":"PHASE1","title":"Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2020-12-01","conditions":["Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence"],"enrollment":90,"completionDate":"2022-07-01"},{"nctId":"NCT02655562","phase":"PHASE4","title":"Fractional Concentration of Exhaled NO(FeNO) to Direct The Treatment of Sub-acute Cough","status":"SUSPENDED","sponsor":"Beijing Chao Yang Hospital","startDate":"2016-04","conditions":["Coughing"],"enrollment":200,"completionDate":"2026-02"},{"nctId":"NCT05152004","phase":"NA","title":"Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2018-09-01","conditions":["Helicobacter Pylori Infection"],"enrollment":240,"completionDate":"2022-02-28"},{"nctId":"NCT00852696","phase":"NA","title":"Over Active Bladder Patients Having Sling Surgery","status":"TERMINATED","sponsor":"Cleveland Clinic Florida","startDate":"2008-02","conditions":["Overactive Bladder"],"enrollment":1,"completionDate":"2010-02"},{"nctId":"NCT04167670","phase":"PHASE3","title":"Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2019-12-10","conditions":["Helicobacter Pylori Infection"],"enrollment":1046,"completionDate":"2021-03-18"},{"nctId":"NCT05250050","phase":"PHASE4","title":"Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-03-25","conditions":["Helicobacter Pylori Infection"],"enrollment":388,"completionDate":"2023-03-01"},{"nctId":"NCT01085097","phase":"PHASE2","title":"A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-09-01","conditions":["Lupus Nephritis"],"enrollment":46,"completionDate":"2012-10-24"},{"nctId":"NCT05250245","phase":"PHASE4","title":"Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2020-06-01","conditions":["Overactive Bladder","Obstructive Sleep Apnea","Overactive Bladder Syndrome"],"enrollment":60,"completionDate":"2022-01-01"},{"nctId":"NCT04991662","phase":"PHASE4","title":"Effect of Three Weight-adjusted Vasopressors for Elective Cesarean Delivery","status":"COMPLETED","sponsor":"Xuzhou Medical University","startDate":"2021-10-10","conditions":["Cesarean Section Complications"],"enrollment":78,"completionDate":"2021-12-03"},{"nctId":"NCT04412018","phase":"PHASE2","title":"An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19","status":"COMPLETED","sponsor":"Canadian Medical and Surgical Knowledge Translation Research Group","startDate":"2020-06-04","conditions":["COVID-19","Inflammatory Response"],"enrollment":100,"completionDate":"2020-12-12"},{"nctId":"NCT02730325","phase":"NA","title":"To Evaluate the Impact of SBI on C. Difficile in Hospitalized UC Patients","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2015-12","conditions":["Clostridium Difficile"],"enrollment":10,"completionDate":"2018-01-05"},{"nctId":"NCT00000752","phase":"PHASE2","title":"Preventing Frequent Sinus Infections in HIV-Infected Patients","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections","Sinusitis"],"enrollment":0,"completionDate":"1993-02"},{"nctId":"NCT05061732","phase":"PHASE4","title":"Helicobacter Pylori Eradication and Follow-up","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-09-30","conditions":["Helicobacter Pylori Infection"],"enrollment":4447,"completionDate":"2026-06-30"},{"nctId":"NCT05022628","phase":"PHASE4","title":"Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis","status":"UNKNOWN","sponsor":"Anhui Provincial Hospital","startDate":"2021-09-30","conditions":["HCC","Chemotherapy Effect"],"enrollment":30,"completionDate":"2024-08"},{"nctId":"NCT05023577","phase":"PHASE4","title":"Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-08-26","conditions":["Helicobacter Pylori Infection"],"enrollment":504,"completionDate":"2022-12-30"},{"nctId":"NCT05018923","phase":"PHASE4","title":"Tetracycline Versus Doxycycline for HP Rescue Therapy","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-08-24","conditions":["Helicobacter Pylori Infection"],"enrollment":242,"completionDate":"2022-12-30"},{"nctId":"NCT04909255","phase":"PHASE4","title":"Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder","status":"UNKNOWN","sponsor":"China Medical University Hospital","startDate":"2021-03-23","conditions":["Sjogren's Syndrome","Overactive Bladder Syndrome"],"enrollment":50,"completionDate":"2022-08-15"},{"nctId":"NCT04994262","phase":"NA","title":"The Effect on Thirst, Nausea-Vomiting and Comfort Levels of Menthol Lozenge Applied After Extubation","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2020-05-01","conditions":["Nausea","Vomiting","Thirst"],"enrollment":118,"completionDate":"2021-05-01"},{"nctId":"NCT02651116","phase":"PHASE4","title":"Dextromethorphan Pediatric Acute Cough Study","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-02-25","conditions":["Cough"],"enrollment":131,"completionDate":"2020-03-19"},{"nctId":"NCT03583372","phase":"PHASE3","title":"An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).","status":"COMPLETED","sponsor":"Urovant Sciences GmbH","startDate":"2018-06-14","conditions":["Overactive Bladder"],"enrollment":506,"completionDate":"2019-07-25"},{"nctId":"NCT04287777","phase":"PHASE3","title":"Safety and Efficacy of Mupirocin Gel in Children With Impetigo","status":"COMPLETED","sponsor":"Reig Jofre Group","startDate":"2014-02","conditions":["Impetigo"],"enrollment":467,"completionDate":"2016-11"},{"nctId":"NCT03492281","phase":"PHASE3","title":"A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Urovant Sciences GmbH","startDate":"2018-03-26","conditions":["Overactive Bladder"],"enrollment":1530,"completionDate":"2019-02-04"},{"nctId":"NCT03714919","phase":"PHASE2","title":"A Pilot Study: a Non-opioid Technique for Postoperative Adenoidectomy Pain Relief in Pediatric Patients","status":"COMPLETED","sponsor":"Arlyne Thung","startDate":"2019-08-02","conditions":["Adenoid Hypertrophy"],"enrollment":10,"completionDate":"2019-11-10"},{"nctId":"NCT01302938","phase":"PHASE4","title":"Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-03","conditions":["Overactive Bladder"],"enrollment":18,"completionDate":"2012-08"},{"nctId":"NCT01488578","phase":"","title":"Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-12","conditions":["Overactive Bladder"],"enrollment":11157,"completionDate":"2011-03"},{"nctId":"NCT00137397","phase":"PHASE4","title":"A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-11","conditions":["Urinary Incontinence"],"enrollment":80,"completionDate":"2006-08"},{"nctId":"NCT00143481","phase":"PHASE4","title":"Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-03","conditions":["Urinary Incontinence"],"enrollment":400,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000147978","MMSL":"5286","NDDF":"001829","UNII":"33RU150WUN","VUID":"4019893","CHEBI":"CHEBI:8104","VANDF":"4017853","INN_ID":"4955","RXNORM":"3266","UMLSCUI":"C0031495","chemblId":"CHEMBL1200695","ChEMBL_ID":"CHEMBL61006","KEGG_DRUG":"D01224","DRUGBANK_ID":"DB00397","PUBCHEM_CID":"26934","SNOMEDCT_US":"387335009","SECONDARY_CAS_RN":"154-41-6","MESH_DESCRIPTOR_UI":"D010665"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"2000-","companyName":"Alpharma Us Pharms","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"95%"},"publicationCount":807,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"R01BA01","allCodes":["R01BA01","R01BA51"]},"biosimilarFilings":[],"originalDeveloper":"Alpharma Us Pharms","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"Alpharma Us Pharms","companyId":"alpharma-us-pharms","modality":"Small molecule","firstApprovalDate":"2000","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2000-09-29T00:00:00.000Z","mah":"ALPHARMA US PHARMS","brand_name_local":null,"application_number":""},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2000-09-29T00:00:00.000Z","mah":"ALPHARMA US PHARMS","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2000-09-29T00:00:00.000Z","mah":"ALPHARMA US PHARMS","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2000-09-29T00:00:00.000Z","mah":"ALPHARMA US PHARMS","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2000-09-29T00:00:00.000Z","mah":"ALPHARMA US PHARMS","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2000-09-29T00:00:00.000Z","mah":"ALPHARMA US PHARMS","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:19:30.755938+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}